-
公开(公告)号:US20130034522A1
公开(公告)日:2013-02-07
申请号:US13559995
申请日:2012-07-27
申请人: Maria Rosario , Nathalie Chauret , Shelley George , Tara Lynn Kieffer , Margaret James Koziel , Olivier Nicolas , Louise Proulx
发明人: Maria Rosario , Nathalie Chauret , Shelley George , Tara Lynn Kieffer , Margaret James Koziel , Olivier Nicolas , Louise Proulx
IPC分类号: A61K31/497 , A61K31/7056 , A61P31/14 , A61K38/21
CPC分类号: A61K45/06 , A61K31/4535 , A61K31/454 , A61K31/7056 , A61K2300/00
摘要: A method of improving the pharmacokinetics of VX-222 in a patient infected with HCV comprises co-administering VX-222 and VX-950 to the patient. A method of treating a patient infected with HCV comprises administering VX-222 and VX-950 to the patient, wherein VX-222 is in an amount of about 20 mg to about 400 mg, and wherein VX-950 is in an amount of about 100 mg to about 1,500 mg. A method of treating a patient infected with HCV comprises administering a therapeutically effective amount of VX-222, wherein VX-222 is administered at an amount of about 20 mg to about 2,000 mg once a day.
摘要翻译: 在HCV感染患者中改善VX-222的药代动力学的方法包括向患者共同施用VX-222和VX-950。 治疗感染HCV的患者的方法包括向患者施用VX-222和VX-950,其中VX-222的量为约20mg至约400mg,并且其中VX-950的量为约 100毫克至约1,500毫克。 治疗感染HCV的患者的方法包括施用治疗有效量的VX-222,其中VX-222以约20mg至约2,000mg的量每天一次施用。